Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the ‘select-d’ Pilot Trial

Introduction: Cancer patients with acute venous thromboembolism (VTE) are at increased risk of recurrent thrombosis and anticoagulant-associated bleeding compared to non-cancer patients with VTE. Long-term low molecular weight heparin (LMWH) has hitherto been the standard treatment for cancer patients with VTE. Data comparing LMWH with direct oral anticoagulants in cancer patients with VTE were limited.

Source: Thrombosis Research - April 1, 2018 Category: Hematology Authors: A. Young, A. Marshall, J. Thirlwall, O. Chapman, A. Lokare, C. Hill, D. Hale, J.A. Dunn, A.K. Kakkar, M. Levine, on behalf of the select-d Collaborative Group Source Type: research